What is the role of thyroid ablation in treating thyroid conditions?

Thyroid Ablation: Role and Clinical Applications

Primary Indication: Radioiodine Ablation for Differentiated Thyroid Cancer

Radioiodine (RAI) ablation following total thyroidectomy is indicated for high-risk differentiated thyroid cancer patients, not indicated for low-risk patients, and should be individualized for intermediate-risk patients based on specific risk factors. 1

Risk-Stratified Approach to RAI Ablation

High-Risk Patients (RAI Recommended):

• Known distant metastases 1
• Documented lymph node metastases 1
• Gross extrathyroidal extension regardless of tumor size 1
• Primary tumor size >2 cm even without other high-risk features 1
• Macroscopic tumor invasion or incomplete tumor resection 1

Low-Risk Patients (RAI Not Recommended):

• Unifocal cancer <1 cm without other high-risk features 1
• Multifocal cancer when all foci are <1 cm without high-risk features 1
• Complete surgery with intrathyroidal tumor, no aggressive histology, and no metastases 1

Intermediate-Risk Patients (Decision Required):

• Microscopic invasion into perithyroidal soft tissues 1
• Aggressive histology (tall cell, columnar, insular, solid variant) or vascular invasion 1
• Primary tumor 1-2 cm with favorable features 1

Optimal RAI Ablation Protocol

Preparation with recombinant human TSH (rhTSH) while continuing levothyroxine therapy is the method of choice, demonstrating equal efficacy to thyroid hormone withdrawal with superior patient acceptance. 1

• rhTSH preparation shows similar rates of persistent disease and recurrence compared to traditional thyroid hormone withdrawal 1
• Lower activities of 1110-1850 MBq (30-50 mCi) achieve successful ablation, even with lymph node metastases 1
• rhTSH-assisted ablation successfully treats ~70% of locoregional lymph nodes and ~70% of pulmonary micrometastases 1

Post-Ablation Surveillance Strategy

At 6-12 months post-ablation, perform rhTSH-stimulated thyroglobulin measurement with neck ultrasound to stratify ongoing risk. 1

• Undetectable thyroglobulin (<1.0 ng/mL) with negative ultrasound: decrease LT4 dose to maintain TSH in normal range, perform yearly evaluation 1
• Detectable thyroglobulin (0.1-2 ng/mL) without other abnormalities: repeat rhTSH with thyroglobulin at yearly intervals 1
• Thyroglobulin ≥2.0 ng/mL or other abnormalities: pursue imaging for disease localization 1
• Post-therapy whole body scan upstages disease in 6-13% of cases 1

---

Alternative Indication: Thermal Ablation for Thyroid Nodules

Ultrasound-guided thermal ablation (radiofrequency or laser) is a first-line treatment for symptomatic benign thyroid nodules and a valid option for recurrent well-differentiated thyroid cancer in high surgical risk patients. 1, 2

Indications for Thermal Ablation

Benign Thyroid Nodules:

• Symptomatic benign nodules causing compression, cosmetic concerns, or discomfort 1, 2
• Autonomously functioning thyroid nodules when surgery/radioiodine are contraindicated or refused 3
• Volume reduction rates of 60-90% with excellent safety profile 4

Malignant Disease (Limited Role):

• Recurrent well-differentiated thyroid cancer in patients at high surgical risk 5, 2
• T1aN0M0 papillary thyroid carcinomas in highly selected cases 1
• NOT recommended for Thy3 nodules (follicular lesions), as it delays surgery in malignancy and may promote tumor progression 6

Safety Profile and Complications

Overall complication risk is 2-3%, with permanent complications <1%, making thermal ablation safer than thyroid surgery. 4

Common Minor Complications:

• Pain (most frequent, up to 100% experience mild discomfort) 1
• Transient voice changes (0.5-7.9%, usually recover within 1-3 days) 1
• Bleeding/hematoma (0.35-17%, typically resolves with compression) 1

Rare Major Complications:

• Permanent vocal cord paralysis (0.04-0.17%) 1
• Nodule rupture (0.08-0.21%, treat with NSAIDs early) 1
• Nerve injuries including sympathetic ganglia and brachial plexus (0.04-0.08%) 1

Critical Technical Considerations

Adequate hydrodissection is essential to reduce nerve injury risk, and moving-shot ablation technique with continuous needle tip monitoring prevents complications. 1

• Insert needle via isthmus approach when possible 1
• Use contrast-enhanced ultrasound immediately post-ablation to assess completeness 1
• NSAIDs recommended for prevention/treatment of nodular rupture in larger nodules 1

---

Key Clinical Pitfalls to Avoid

Never use thermal ablation for follicular neoplasms (Thy3 nodules), as one session does not affect subsequent surgery but delays definitive treatment if malignancy is present. 6

Do not perform thermal ablation for diffuse sclerosing papillary carcinoma or malignancies other than papillary thyroid carcinoma. 7

Ensure patients with autonomously functioning nodules understand that thermal ablation remains second-line to surgery/radioiodine, with variable success rates for symptom relief. 3

For post-thyroidectomy RAI ablation, always obtain post-therapy whole body scan as it upstages disease in 6-13% of cases, potentially changing management. 1